The occurrence of hypercholesteremia in the nephrotic state is a long recognized phenomenon (1), but its mechanism remains to be determined. Apparently the hypercholesteremia cannot be ascribed to a primary "lipoid degeneration" of the kidney (2).

Recently, studies from this laboratory (3–6) have indicated that there is a marked derangement of cholate metabolism in certain clinical and experimental states of hypercholesteremia. It therefore was considered of interest to investigate the metabolism of this particular steroid in both clinical and experimental nephrosis.

I. The Cholate: Cholesterol Relationship in Clinical Nephrosis

A. Methods

Samples of blood serum were obtained from 18 patients suffering from nephrosis for periods of time varying from one to 24 months. There were 12 males and 6 females, varying in age from 3 to 65 years. "Lipoid" nephrosis was believed present in 11 instances, the nephrotic stage of chronic glomerulonephritis in six patients, and Kimmelstiel-Wilson syndrome with nephrosis in one case. Serum cholesterol and cholate concentrations were determined in each instance, according to technics previously described (7, 8).

B. Results

The cholate content of the serum invariably was elevated if the patients also were hypercholesteremic (see Table I). Thus, the serum cholesterol concentrations of 15 nephrotic patients with hypercholesteremia varied from 450 to 1060 mg. per 100 cc., and their serum cholates from 10.0 to 44.0 mg. per 100 cc. These values were in marked contrast to those obtained from 25 normal human subjects in whom the serum cholesterol ranged from 110 to 280 mg. per 100 cc., and the serum cholate from 1.7 to 7.2 mg. per 100 cc.

On the other hand, the serum cholate concentrations were found to be normal (1.0, 6.4, 5.0 mg. per 100 cc.) in three nephrotic patients with normal serum cholesterol levels (110, 250, 200 mg. per 100 cc., respectively). This finding of "hypercholatemia" in nephrotic patients only when they also exhibited hypercholesteremia prompted the following experimental investigations:

II. The Cholate: Cholesterol Relationship in Experimental Nephrosis

TABLE I

<table>
<thead>
<tr>
<th>Type of patient</th>
<th>No. of patients</th>
<th>Average plasma cholesterol (mg./100 cc.)</th>
<th>Average plasma cholate (mg./100 cc.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal control</td>
<td>25</td>
<td>228</td>
<td>5.3</td>
</tr>
<tr>
<td></td>
<td>Range:</td>
<td>(110–280)</td>
<td>(1.7–7.2)</td>
</tr>
<tr>
<td></td>
<td>S.E. Mean:</td>
<td>±8.7</td>
<td>±0.26</td>
</tr>
<tr>
<td>Nephrotic</td>
<td>15</td>
<td>695</td>
<td>19.2</td>
</tr>
<tr>
<td>(hypercholesteremic)</td>
<td></td>
<td>(450–1060)</td>
<td>(10.0–44.0)</td>
</tr>
<tr>
<td></td>
<td>S.E. Mean:</td>
<td>±45.0</td>
<td>±2.8</td>
</tr>
<tr>
<td>Nephrotic</td>
<td>3</td>
<td>180</td>
<td>4.4</td>
</tr>
<tr>
<td>(normocholesteremic)</td>
<td></td>
<td>(110–250)</td>
<td>(1.0–6.4)</td>
</tr>
</tbody>
</table>

The studies of Heymann and Lund (9) have shown that the chronic disease produced in rats by the injection of rabbit anti-rat kidney serum closely simulates the nephrotic state as it is observed in human subjects. This method, therefore,
was utilized to study cholate metabolism in experimental nephrosis.

(1) Methods

Rabbit anti-rat kidney serum, prepared and sent to us by Dr. A. I. Knowlton (10), was injected intravenously into immature (4 to 8 weeks old) male rats (Long-Evans strain). One-third cubic centimeter of this serum was injected into each of 30 rats on each of two successive days. Renal disease, as indicated by the onset of marked albuminuria and hyperlipemia (9), developed within one week in all but two rats.

Plasma cholesterol and cholate concentrations were determined in 22 rats prior to, and one week following, the injections of anti-rat kidney serum. Similar analyses were obtained in a group of 10 normal control animals.

(2) Results

Both hypercholesteremia and hypercholatemia consistently were found (see Table II). The average plasma cholesterol of the 22 nephrotic rats rose from 71 mg. per 100 cc. (prior to the injection of immune serum) to 460 mg. per 100 cc., one week after the injections of anti-rat kidney serum. The average plasma cholate concentration of the same rats rose from 5.9 to 23.1 mg. per 100 cc.

B. The rate of disappearance of cholate from the blood of nephrotic rats following its intravenous injection

(1) Methods

In order to test the ability of the nephrotic rats to eliminate cholate from their blood, the following experiment was performed. Twenty-five milligrams of sodium cholate were injected intravenously into 11 of the above, nephrotic rats and into 10 control animals. Nephrotic rats were selected whose plasma cholate levels were only moderately elevated at the time of the injection. In each instance samples of blood plasma were obtained at four different times; prior to, and immediately and one and two hours after the injection of sodium cholate.

(2) Results

The intravenous injection of cholate induced a considerable and comparable rise of plasma cholate in both the nephrotic and the control animals (see Table III). The excess cholate largely disappeared from the plasma of the control group of rats within one hour after its administration. It was eliminated entirely at the end of two hours. However, considerable elevation of plasma cholate was found in the nephrotic rats at the end of one hour and this persisted even two hours after the cholate injection. Thus, there appeared to be a delay in the disappearance of the injected cholate from the plasma of the nephrotic rats.

C. The effect of cholate administration upon the plasma cholesterol of nephrotic rats

(1) Methods

Heymann and Lund (9) observed that the initial hypercholesteremia which developed in nephrotic rats soon decreased to somewhat lower although still elevated levels. This finding prompted the following experiment: One hundred milligrams of cholate were fed daily by gastric intubation to 11 of 17 nephrotic rats (one week after the injection of immune serum). The same amount of cholate was given to 11 of 19 control animals. The plasma cholesterol was determined in each instance prior to the feeding of cholate and again five days later. Similar determinations were obtained in the remaining nephrotic and control rats that did not receive cholate feedings. All rats were fed the stock laboratory ration.

(2) Results

The elevated plasma cholesterol levels of the 11 nephrotic rats to which cholate was fed, were maintained; their average plasma cholesterol rose from 495 mg. per 100 cc. to 508 mg. per 100 cc. (see Table IV). On the other hand, the average plasma cholesterol of the six nephrotic rats not receiving

<table>
<thead>
<tr>
<th>TABLE II</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average plasma cholesterol and cholate concentration of nephrotic rats</td>
</tr>
<tr>
<td>Type of rat</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Nephrotic</td>
</tr>
<tr>
<td>Range:</td>
</tr>
<tr>
<td>Control</td>
</tr>
<tr>
<td>Range:</td>
</tr>
</tbody>
</table>
cholate feedings fell from 417 mg. per 100 cc. to 211 mg. per 100 cc. The cholate feedings also induced an elevation of plasma cholesterol in the normal animals, their average concentration rising from 73 mg. per 100 cc. to 99 mg. per 100 cc.

**DISCUSSION**

The studies described above have shown that an excess of cholate is present in the blood plasma of nephrotic human subjects, as well as in the plasma of rats with experimentally induced nephrosis, whenever hypercholesteremia also is present. This excess of cholate may well be responsible for the reduced surface tension of nephrotic blood, a phenomenon first described by Clausen (11) and later confirmed by Leiter (12).

**TABLE III**

Rate of disappearance of injected cholate from plasma of nephrotic rats

<table>
<thead>
<tr>
<th>Type of rat</th>
<th>No. of rats</th>
<th>Average weight gm.</th>
<th>Plasma cholate concentration, mg./100 cc.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Before Injection</td>
</tr>
<tr>
<td>Nephrotic</td>
<td>11</td>
<td>208 (138–260)</td>
<td>11.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>±1.6</td>
<td>41.9</td>
</tr>
<tr>
<td>Range:</td>
<td></td>
<td></td>
<td>(7.4–20.9)</td>
</tr>
<tr>
<td>S.E. Mean:</td>
<td></td>
<td></td>
<td>(11.2–15.6)</td>
</tr>
<tr>
<td>Control</td>
<td>10</td>
<td>249 (235–267)</td>
<td>5.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>±0.17</td>
<td>41.3</td>
</tr>
<tr>
<td>Range:</td>
<td></td>
<td></td>
<td>(4.4–6.2)</td>
</tr>
<tr>
<td>S.E. Mean:</td>
<td></td>
<td></td>
<td>(3.5–2.2)</td>
</tr>
</tbody>
</table>

* 25 mg. sodium cholate injected intravenously.

Other studies from this laboratory (4) have shown that hypercholateremia is almost invariably present in various clinical states of hypercholesteremia. This fact in itself might be only of incidental interest were it not for the observation (3) that when hypercholateremia is induced experimentally in the rat, a state of hypercholesteremia immediately develops. In view of these findings, the possible relationship between the excess cholate and cholesterol in the blood of the nephrotic animal may have considerable importance. This is discussed more extensively in a forthcoming study (13).

**SUMMARY**

An excess accumulation of bile acid (hypercholateremia) was found in the blood of human subjects with nephrosis and in the blood of rats in which experimental nephrosis had been induced by injection of anti-rat kidney serum, whenever hypercholesteremia also was present. The nephrotic rat also was found to exhibit a diminished ability to rid his blood of excess injected cholate. Finally, the feeding of cholate to nephrotic rats appeared to prevent the decrease of plasma cholesterol, which usually occurred, following its initial maximal rise.

**REFERENCES**

3. Friedman, M., and Byers, S. O., Cholic acid: an ade-


